期刊
INTERNATIONAL JOURNAL OF OBESITY
卷 39, 期 1, 页码 82-84出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ijo.2014.59
关键词
healthy aging; reverse causation; obesity epidemic; survival advantage; body mass index
资金
- Allergan Inc
- Metagenics
- iNova Pharmaceuticals
- Medtronic
- Servier Australia
- Abbott
- Allergan Inc.
- Pfizer
- Wyeth Pharmaceuticals
- Servier
The 'obesity paradox' refers to observations that run counter to the thesis that normal weight (BMI 18.5-24.9 kg/m(2)) provides the lowest mortality and higher weight is associated with greater mortality. We argue that the weight of lowest mortality is influenced by aging and chronic disease, with mortality advantage extending into the overweight and even class I obese ranges under some circumstances. A focus on quality nutrition, physical activity, fitness, and maintaining function in these weight ranges may be preferable to a focus on intentional weight loss, which has uncertain effects. The 'obesity paradox' is no 'paradox' if one defines and interprets 'ideal' weight appropriately.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据